Windy City Media Group Frontpage News

THE VOICE OF CHICAGO'S GAY, LESBIAN, BI, TRANS AND QUEER COMMUNITY SINCE 1985

home search facebook twitter join
Gay News Sponsor Windy City Times 2021-09-01
DOWNLOAD ISSUE
Donate

Sponsor
Sponsor

  WINDY CITY TIMES

PrEP options likely to change following Truvada patent expiration
by Matt Simonette
2021-03-04

This article shared 1603 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email


Among the myriad challenges facing HIV/AIDS advocates and healthcare providers has been increasing use of pre-exposure prophylaxis, or PrEP, among persons at risk for HIV transmission. A PrEP intervention, which usually consists of taking the oral medication Truvada, has been shown to decrease the risk of transmission by more than 90 percent.

Truvada was approved for PrEP use by the Food and Drug Administration in 2012 and, since then, has been widely prescribed by physicians to help at-risk patients prevent HIV transmission (it was earlier used to treat persons living with HIV). But Truvada's patent expiration in 2020 means both generic options for consumers are forthcoming and that a competing drug, Descovy, by the same manufacturer, is already on the market.

Some advocates are looking forward to having lower-cost options available. AIDS Foundation of Chicago (AFC) Senior Director of Prevention Advocacy and Gay Men's Health Jim Pickett suspects that "lower drug costs will lower the cost of access and alleviate some pressure on the system."

He added, "With PrEP, the costs are not just about the drug. There are costs affiliated with seeing your doctor, having blood work done, being tested for HIV and STI's. It's important to remember that services that come along with PrEP are part of the program—PrEP isn't just a prescription. If our system can spend less on the drug, there's arguably more money to cover those other things which can be prohibitive for people."

The cost of Truvada—which is a combination of the drugs known generically as tenofovir disoproxil fumarate and emtricitabine—has indeed been a key deterrent to widespread PrEP implementation. A month's supply of the medication is often $1,500-2,000. Nevertheless, many insurers cover Truvada in their formularies, and the medication's manufacturer, Foster City, California-based Gilead Sciences, provides consumer assistance for monthly co-payments their plans require.

Various public health agencies have also made PrEP access a central component to long-term strategies that eliminate new HIV transmissions, such as the Getting to Zero initiative launched in Illinois in late 2018. The federal government announced a similar program with PrEP interventions playing a central role in early 2019.

Nevertheless, PrEP adoption numbers remain far behind where advocates and providers want to see them. Getting the message about PrEP to white gay men has been a relatively minimal challenge, but communicating that same message to diverse audiences at risk, such as transgender women or young Black men, remains problematic. Usage in the southern United States, where a large number of new HIV transmissions take place, is also low.

In late 2019, Gilead announced it would donate a five-year supply of Truvada to 200,000 people. Their Truvada patent expired in late 2020. The company reached an exclusivity agreement for six months Israeli pharmaceutical manufacturer Teva for a generic version of tenofovir disoproxil fumarate and emtricitabine. Starting in spring 2021, Teva's exclusivity window expires and any manufacturer can produce a generic version of tenofovir disoproxil fumarate and emtricitabine.

Gilead still intends to remain a player in manufacturing and distributing medications for PrEP, however. In 2019, it received approval for use of Descovy as a PrEP intervention and has aggressively marketed the new drug as a replacement for Truvada. Google users who search "Truvada generic" will likely spot an advertisement for Descovy toward the top of their results.

Among the advantages of Descovy, according to Gilead, are reduced chances of complications to kidneys or bone density, which are stated side-effects to Truvada. But Descovy shares the same high cost as Truvada, about $16,600-20,000 a year, according to aidsmap.com .

Many advocates and providers say that there is no need for a "mass exodus" from Truvada to Descovy for PrEP users, Pickett said.

"In terms of prescribing for PrEP, the vast majority of people using Truvada for PrEP have absolutely zero clinical need to switch over to Descovy," he added. "The only clinical reason to switch would be if you have some underlying kidney or bone disease, or if Truvada is giving your kidneys a hard time."

Gilead could not provide a spokesperson to comment on Descovy by this article's deadline. Shortly after Descovy was approved for PrEP in October 2019, Daniel O'Day, Gilead's chairman and CEO, said the new medication nevertheless "provides a new HIV prevention option that matches Truvada's high efficacy with statistically significant improvements in renal and bone safety, which can be an important consideration as people at risk increasingly use PrEP for longer periods of time."

Prior to her appointment as director of the Centers for Disease Control and Prevention, Rochelle Walensky, MD, was lead author on a March 2020 Annals of Internal Medicine study which concluded that mitigating for Truvada's side-effects with a new medication was outweighed by the benefits of a lower-cost generic substitute for Truvada. Other researchers also have expressed concern that Descovy has not been tested on as diverse a population as Truvada has been.

"We already are seeing insurance companies pointing people to the generic alternative—when you are prescribed PrEP, the insurance company might cover the generic form of Truvada," Pickett said. "They may or may not be inclined to cover Truvada itself. We are also seeing insurance companies put in utilization-management for Descovy, so if you are prescribed Descovy, the doctor has to show clinical need."

Gilead has also been involved in extensive litigation with the federal government regarding the PrEP-related patents. The CDC sued the company in 2019, maintaining that it had not been properly compensated for federal researchers' contributions to Truvada and Descovy's development. In January 2021, a federal judge rejected the Justice Department's motion to dismiss Gilead's counterclaims that the federal government had been in breach of key contracts, so the litigation will continue.

But for now, a key challenge for stakeholders remains getting the costs under control. Using PrEP represents a collective commitment of time and money for patients, providers and insurers.

In the years ahead, the PrEP landscape will likely change even further. An injectable version of the intervention has proven to be as effective as oral applications. In such a scenario, the medication cabotegravir could be injected and offer two months' worth of protection for patients who don't wish to take a pill every day.

Pickett said he didn't foresee injectable PrEP completely replacing pills however, noting that compliance challenges might only shift for some consumers. While the injection saves the patient from the responsibility of taking a pill, they'd still need a bimonthly appointment to receive it.

"I don't see it as replacing [oral medication]—I see it as being additive," Pickett said. "I see it drawing in people who struggle with PrEP because it is a pill, or aren't interested because it's a pill. Overall, if we do it right and create support systems that make it easy for people to get their shots—imagine being able to do it at Walgreens—I'll be super-excited about it. It means people having more options and more protection."


This article shared 1603 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email





Windy City Media Group does not approve or necessarily agree with the views posted below.
Please do not post letters to the editor here. Please also be civil in your dialogue.
If you need to be mean, just know that the longer you stay on this page, the more you help us.


  ARTICLES YOU MIGHT LIKE

Gay News

NATIONAL Carl Bean dies, LGBT History Month, military events, Dykes on Bikes 2021-09-19
- Archbishop Carl Bean—an openly gay former Motown singer, longtime AIDS activist and leader in the LGBTQ church movement—died at age 77, The New York Daily News reported. In a statement entitled "The Giant Sleeps," the Unity ...


Gay News

HHS awards $48M to health centers to expand HIV prevention, treatment 2021-09-16
- On Sept. 16, the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), awarded more than $48 million to 271 HRSA-supported health centers across 26 states, Puerto Rico and ...


Gay News

New safety precautions announced for 30th annual AIDS Run & Walk Chicago Oct. 2 2021-09-08
--From a press release - CHICAGO — AIDS Foundation Chicago (AFC) has announced proof of full vaccination or negative COVID-19 test result within 72 hours of event will be required for all in-person participants for the 30th annual AIDS Run & ...


Gay News

HIV AT 40: Global activist Phill Wilson talks Chicago, the '80s and vaccines 2021-09-01
- Phill Wilson is one of the best-known HIV/AIDS activists/educators around the globe. The Chicago native was the co-founder of the National Black Lesbian and Gay Leadership Forum and the National Task Force on AIDS Prevention. He ...


Gay News

Feds expand insurers' requirements for PrEP coverage 2021-08-26
- Insurers and service-providers have until September to comply with a new federal guidance requiring insurance companies to cover the entire cost of PrEP (pre-exposure prophylaxis) interventions. Many insurers have been ...


Gay News

NATIONAL Ann Arbor ban, Buttigieg, NYC settlement, Gloria Allred 2021-08-22
- Using gay conversion therapy on minors to try to change their sexual orientation or gender identity is now officially banned in Ann Arbor, Michigan, according to MLive.com. "So-called conversion therapy is, of course, an abomination," Mayor ...


Gay News

Chicago Academy's 25th annual AIDS benefit show Sept. 24-25 2021-08-12
- Each year, Chicago Academy for the Arts students produce and perform in a variety show to support HIV/AIDS research and organizations. The 25th Annual AIDS Benefit will take place Sept. 24-25 at The Academy, 1010 W. ...


Gay News

U.S. Conference on HIV/AIDS moves to virtual 2021-08-10
--From a press release - Aug. 10, 2021 - NMAC today announced that the 2021 US Conference on HIV/AIDS will move from an in-person conference to a virtual meeting due to the continued spread of the Delta variant of the Covid ...


Gay News

DaBaby apologizes for 'misinformed' comments about AIDS, LGBTQ people 2021-08-03
- After his headlining sets at Lollapalooza, Governors Ball and Day N Vegas festivals were canceled within 24 hours of each other, rapper DaBaby issued another apology to the LGBTQ community, Variety reported. "Social Media moves so ...


Gay News

PrEP pills to be free for insured people 2021-07-25
- The U.S. government has stated that nearly all health insurers must cover the entire cost of HIV prevention treatments, according to U.S. News & World Report. That includes the two approved pre-exposure prophylaxis (PrEP) drugs Truvada ...


Gay News

Summit looking for BIPOC LGBTQ+ attendees 2021-07-22
- Pride Action Tank (PAT) and AIDS Foundation Chicago (AFC) will co-host "Co-Creating Futures: A BIPOC LGBTQ+ Policy & Practices Summit," starting virtually on Saturday, July 31, 11 a.m.-3:30 p.m. CT. According to the event's webpage, "T ...


Gay News

30th Annual 2021 AIDS Run & Walk Chicago to benefit 25 groups, AIDS Foundation Chicago 2021-07-13
--From a press release - CHICAGO — Now in its 30th year, AIDS Run & Walk Chicago returns to Soldier Field on Saturday, October 2 to support individuals living with and vulnerable to HIV/AIDS and other chronic illnesses. AIDS Run & ...


Gay News

NATIONAL Spa incident, N.J. items, AIDS gala, Tenn. lawsuits 2021-07-11
- Tensions rose between protesters and counterprotesters in Los Angeles over a spa incident involving a transgender woman, The Hill reported. Recently, a cisgender woman complained to staff at Wi Spa in Koreatown after a transgender woman ...


Gay News

ALMA, AFC host Latino/a/x-focused COVID-19 grand rounds virtual presentation 2021-07-08
- Association of Latino/as/x Motivating Action (ALMA) and AIDS Foundation Chicago (AFC) hosted a "COVID-19 Grand Rounds—Systemic Racism and Health Disparities: The Impact of COVID-19 on Latino/a/x populations" virtual presentation July ...


Gay News

Gilead requests approval of twice-a-year HIV medication 2021-07-02
- Biopharmaceutical company Gilead Sciences recently submitted a new drug application to the U.S. Food and Drug Administration—and it's for the drug lenacapavir, a long-acting HIV inhibitor that is under clinical ...


 



Copyright © 2021 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 

 

 

TRENDINGBREAKINGPHOTOS







Sponsor
Sponsor


 



Donate


About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots      OUT! Guide     
Identity      BLACKlines      En La Vida      Archives      Advanced Search     
Windy City Queercast      Queercast Archives     
Press  Releases      Join WCMG  Email List      Email Blast      Blogs     
Upcoming Events      Todays Events      Ongoing Events      Bar Guide      Community Groups      In Memoriam      Outguide Categories      Outguide Advertisers      Search Outguide      Travel      Dining Out      Privacy Policy     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.